"Camptothecin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.
| Descriptor ID |
D002166
|
| MeSH Number(s) |
D03.132.151
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Camptothecin".
Below are MeSH descriptors whose meaning is more specific than "Camptothecin".
This graph shows the total number of publications written about "Camptothecin" by people in this website by year, and whether "Camptothecin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 2 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 4 | 0 | 4 |
| 1999 | 2 | 0 | 2 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 8 | 0 | 8 |
| 2003 | 3 | 0 | 3 |
| 2004 | 8 | 1 | 9 |
| 2005 | 2 | 5 | 7 |
| 2006 | 6 | 3 | 9 |
| 2007 | 3 | 3 | 6 |
| 2008 | 3 | 3 | 6 |
| 2009 | 4 | 3 | 7 |
| 2010 | 2 | 3 | 5 |
| 2011 | 1 | 4 | 5 |
| 2012 | 2 | 2 | 4 |
| 2013 | 0 | 3 | 3 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 2 | 5 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 4 | 5 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 2 | 2 |
| 2024 | 3 | 2 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Camptothecin" by people in Profiles.
-
Phase II Parallel Arm Study of Sacituzumab Govitecan-Hziy in Patients With Advanced Thymoma or Thymic Carcinoma. Clin Lung Cancer. 2025 May; 26(3):165-167.
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Res Treat. 2024 Nov; 208(1):203-214.
-
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20; 42(24):2860-2872.
-
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study. Future Oncol. 2022 Sep; 18(27):3011-3020.
-
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. Am J Clin Oncol. 2022 08 01; 45(8):366-372.
-
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 05; 13(4):469-479.
-
Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons. Cell Chem Biol. 2021 06 17; 28(6):776-787.e8.
-
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2021 01 01; 27(1):267-275.